4-(4-Methyl-1-piperazinyl)-2-[(4-tetrahydropyranyl)(2,2,2-trifluoroacetyl)amino]benzoic Acid Trifluoroacetate
[CAS# 1034975-62-6]

Identification

• Classification: Pharmaceutical intermediate >> Heterocyclic compound intermediate
• Name: 4-(4-Methyl-1-piperazinyl)-2-[(4-tetrahydropyranyl)(2,2,2-trifluoroacetyl)amino]benzoic Acid Trifluoroacetate
• Molecular Formula: C₂₁H₂₅F₆N₃O₆
• Molecular Weight: 529.43
• CAS Registry Number: 1034975-62-6
• SMILES: CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)O)N(C3CCOCC3)C(=O)C(F)(F)F.C(=O)(C(F)(F)F)O

Discovory and Applicatios

The compound 4-(4-Methyl-1-piperazinyl)-2-[(4-tetrahydropyranyl)(2,2,2-trifluoroacetyl)amino]benzoic Acid Trifluoroacetate was discovered during an extensive research initiative aimed at synthesizing new molecules with potential therapeutic applications. The synthesis of this complex molecule involves the strategic incorporation of piperazine, tetrahydropyran, and trifluoroacetyl groups into a benzoic acid framework. This discovery resulted from efforts to design compounds with enhanced pharmacological properties, including improved bioavailability and specificity for target enzymes and receptors. The synthesis of this compound represents a significant advancement in medicinal chemistry, providing a promising scaffold for drug development.

The compound 4-(4-Methyl-1-piperazinyl)-2-[(4-tetrahydropyranyl)(2,2,2-trifluoroacetyl)amino]benzoic Acid Trifluoroacetate exhibits a wide range of potential applications, primarily in the pharmaceutical industry. One of the most promising applications is in the field of neurology. Its structure suggests it can cross the blood-brain barrier, making it a candidate for treating central nervous system (CNS) disorders. The compound's ability to interact with neurotransmitter receptors and enzymes involved in CNS function indicates potential efficacy in treating conditions such as depression, anxiety, and schizophrenia. By modulating neurotransmitter levels, it can help restore balance in brain chemistry, alleviating symptoms of these disorders.

In addition to its neurological applications, the compound shows potential in oncology. Its unique chemical structure allows it to inhibit specific cancer-related enzymes and pathways, potentially slowing down tumor growth and inducing apoptosis in cancer cells. The trifluoroacetyl and piperazine moieties enhance its ability to bind to these targets with high specificity, making it a promising candidate for developing targeted cancer therapies.

The anti-inflammatory properties of this compound also present opportunities for treating chronic inflammatory diseases. By inhibiting key enzymes in the inflammatory pathway, it can reduce inflammation and provide relief for conditions such as rheumatoid arthritis, inflammatory bowel disease, and other autoimmune disorders. Its ability to modulate the immune response makes it a valuable addition to the arsenal of anti-inflammatory agents.

Moreover, 4-(4-Methyl-1-piperazinyl)-2-[(4-tetrahydropyranyl)(2,2,2-trifluoroacetyl)amino]benzoic Acid Trifluoroacetate could serve as a research tool in biochemical studies. Its interaction with various enzymes and receptors can help elucidate the mechanisms underlying several diseases and guide the development of new therapeutic targets. Researchers can use this compound to study enzyme inhibition, receptor binding, and the effects of these interactions on cellular processes.

Finally, the compound's stability and specificity make it suitable for developing advanced drug delivery systems. Its chemical properties can be leveraged to create formulations that deliver therapeutic agents directly to the site of action, enhancing the efficacy and minimizing side effects. This targeted delivery approach is particularly beneficial in treating localized conditions, ensuring higher concentrations of the drug reach the affected area.